Hana Vosmikova
Overview
Explore the profile of Hana Vosmikova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malapelle U, Chen C, de Alava E, Hofman P, Kazdal D, Kim T, et al.
J Pathol Clin Res
. 2025 Mar;
11(2):e70018.
PMID: 40052485
Current European/US guidelines recommend that molecular testing in advanced non-small cell lung cancer (aNSCLC) be performed using next-generation sequencing (NGS). However, the global uptake of NGS is limited, largely owing...
2.
Laco J, Vosmikova H, Satankova J, Dedkova J, Mejzlik J, Chrobok V, et al.
Virchows Arch
. 2024 Nov;
PMID: 39565412
This report documents the first case of a conventional (bone-type) giant cell tumor of the larynx, in which the diagnosis was confirmed by molecular genetic analysis. A 50-year-old non-smoking man...
3.
Pleskacova Z, Bartos M, Vosmikova H, Dolezal R, Krupa P, Vitovcova B, et al.
Biomedicines
. 2024 Jun;
12(6).
PMID: 38927417
: Although several prognostic factors for survival have been identified in glioblastoma, there are numerous other potential markers (such as hemoglobin) whose role has not yet been confirmed. The aim...
4.
Dvorakova K, Skarkova V, Vitovcova B, Soukup J, Vosmikova H, Pleskacova Z, et al.
BMC Cancer
. 2024 Apr;
24(1):509.
PMID: 38654280
Background: Glioblastoma is a malignant and aggressive type of central nevous system malignancy characterized by many distinct biological features including extensive hypoxia. Hypoxia in glioblatoma associates with complex signaling patterns...
5.
Pavelkova L, Taborska E, Syding L, Plackova K, Simonova E, Hladikova K, et al.
Transl Oncol
. 2024 Jan;
41:101884.
PMID: 38242007
The profile of the antitumor immune response is an important factor determining patient clinical outcome. However, the influence of the tissue contexture on the composition of the tumor microenvironments of...
6.
Hanusova V, Matouskova P, Manethova M, Soukup J, John S, Zofka M, et al.
Cancer Invest
. 2023 Nov;
41(10):837-847.
PMID: 37997798
Colorectal cancer (CRC) is the fourth most commonly diagnosed malignant condition in the world. Micro RNAs (miRNAs) as well as epithelial to mesenchymal transition (EMT) play an important role in...
7.
Skarkova V, Vitovcova B, Matouskova P, Manethova M, Kazimirova P, Skarka A, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291930
(1) Background: N-cadherin expression, epithelial-to-mesenchymal transition (EMT) and aggressive biological phenotype of tumor cells are linked although the underlying mechanisms are not entirely clear. (2) Methods: In this study, we...
8.
Birknerova N, Kovarikova H, Baranova I, Prikrylova A, Laco J, Vosmikova H, et al.
Epigenetics
. 2022 Jan;
17(11):1301-1310.
PMID: 34974810
Recently, an increasing incidence of HPV-induced oropharyngeal squamous cell carcinoma (OPSCC) has been observed. Moreover, locoregionally advanced stages require a combined modal approach, and the prognosis is poor. Therefore, it...
9.
Sirak I, Laco J, Vosmikova H, Mell L, Herrera F, Senkerikova M, et al.
Pathol Oncol Res
. 2021 Dec;
27:1610003.
PMID: 34970085
Small cell carcinoma of hypercalcemic type (SCCOHT) is a rare gynaecological neoplasm, originating mostly in the ovaries. Cervical origin of this very aggressive malignancy with unknown histogenesis is an extremely...
10.
Kopecky J, Kubecek O, Priester P, Vosmikova H, cermakova E, Kyllarova A
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
. 2021 Aug;
166(4):393-404.
PMID: 34446937
Background: The treatment and prognosis of metastatic melanoma have changed during the last decade to include immunotherapy or targeted therapy as standard therapeutic options for BRAF-mutated melanoma. However, predictive and/or...